 Erwinaze has been already used in clinical practice for treatment of patients with acute leukemia with known side effect profile. For this reason, in this protocol, we use the 333 design for evaluation of safety based on pre-determined dose-limiting toxicities DLT. In the 333 design, the dose escalation rules proceed by adjusting the dose in cohorts of 3 to 9 patients per three dose levels:20,000 IUm2 dose cohort -1, 25,000 IUm2 dose cohort 0, 30,000 IUm2 dose cohort 1. The goal is to determine the Recommended Phase 2 Dose RP2D 